Indonesia Generics and Biosimilars
Indonesia Generics and Biosimilars
$2,995.00
In 2011, branded generics accounted for 89% of Indonesia’s overall prescription pharmaceutical market, which was valued at IDR25.04tn ($2.84bn). The overwhelming dominance of generics – both branded and unbranded – leaves very little room for innovative products, other than those whose patents have already expired (i.e. “long-listed drugs”).
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
In 2011, branded generics accounted for 89% of Indonesia’s overall prescription pharmaceutical market, which was valued at IDR25.04tn ($2.84bn). The overwhelming dominance of generics – both branded and unbranded – leaves very little room for innovative products, other than those whose patents have already expired (i.e. “long-listed drugs”).
Government policy is geared towards expanding the uptake of unbranded generics, which are likely to play a key role in the new universal health insurance scheme, which is due to be phased in from January 2014.
CONTENTS
4 EXECUTIVE SUMMARY
4 Key findings
5 MARKET SIZE
6 GENERICS DRIVERS AND RESISTORS
6 Drivers
6 Resistors
8 KEY GENERICS PLAYERS
9 BIOSIMILARS
10 BIBLIOGRAPHY
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
France Generics and Biosimilars 
Sign up to the